# US 2022/0016184 A1 · Compositions comprising bacterial strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016184 A1
- Document ID: US20220016184A1
- Status: Published application
- Kind: A1
- Application number: 17/382,426
- Filed: 2021-07-22
- Published: 2022-01-20
- Earliest claimed: 2017-05-22
- Assignees: 4D Pharma Research Limited
- Applicants: 4D Pharma Research Limited
- Inventors: Helene SAVIGNAC; Imke Elisabeth MULDER; Alexander James STEVENSON
- Web page: https://patentgrep.com/patent/US20220016184A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 1/20: Bacteria; Culture media therefor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions comprising bacterial strains for treating and preventing brain injury.

## Claims

### Claim at position 1

-31. (canceled)

### Claim 32

A method of treating a brain injury in a subject in need thereof, comprising administering to the subject a composition that comprises a therapeutically effective amount of a bacteria strain of the genus Blautia, wherein the bacteria strain comprises a 16S rRNA gene sequence having at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:5, and wherein the administering is effective to treat the brain injury.

### Claim 33 (depends on 32)

The method of claim 32, wherein the administering is effective to improve a loss of neurological function, motor abilities and/or social recognition associated with the brain injury.

### Claim 34 (depends on 32)

The method of claim 32, wherein the brain injury is resulting from a trauma, a tumor, a brain hemorrhage, an encephalitis, a cerebral hypoxia, or a cerebral anoxia.

### Claim 35 (depends on 34)

The method of claim 34, wherein the brain hemorrhage is an intracerebral hemorrhage, an intraparenchymal hemorrhage, an intraventricular hemorrhage, or a subarachnoid hemorrhage.

### Claim 36 (depends on 32)

The method of claim 32, wherein the brain injury is caused by a cerebral amyloid angiopathy, a brain aneurysm, or a cerebral arteriovenous malformation (AVM).

### Claim 37 (depends on 32)

The method of claim 32, wherein the therapeutically effective amount comprises from about 1×103 to about 1×1011 colony forming units (CFU).

### Claim 38 (depends on 32)

The method of claim 32, wherein the composition comprises the bacterial strain in an amount of from about 1×106 to about 1×1011 colony forming units per gram (CFU/g), with respect to the weight of the composition.

### Claim 39 (depends on 32)

The method of claim 32, wherein the composition comprises no more than de minimis amounts of other bacteria strains.

### Claim 40 (depends on 32)

The method of claim 32, wherein the bacteria strain is live.

### Claim 41 (depends on 32)

The method of claim 32, wherein the bacteria strain is capable of at least partially colonizing an intestine of the subject.

### Claim 42 (depends on 32)

The method of claim 32, wherein the administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.

### Claim 43 (depends on 32)

The method of claim 32, wherein the composition is formulated for delivery to an intestine of the subject.

### Claim 44 (depends on 32)

The method of claim 32, wherein the composition is encapsulated.

### Claim 45 (depends on 32)

The method of claim 32, wherein the bacteria strain is lyophilized.

### Claim 46 (depends on 32)

The method of claim 32, wherein the bacteria strain is of the species Blautia hydrogenotrophica.

### Claim 47 (depends on 32)

The method of claim 32, wherein the bacteria strain comprises a 16S rRNA gene sequence having at least 98% sequence identity to the polynucleotide sequence of SEQ ID NO:5

### Claim 48 (depends on 32)

The method of claim 32, wherein the bacteria strain comprises a 16S rRNA gene sequence that is the polynucleotide sequence of SEQ ID NO:5.

### Claim 49 (depends on 32)

The method of claim 32, wherein the bacteria strain is the strain deposited under accession number DSM 14294 or a biotype of the strain deposited under accession number DSM 14294.

### Claim 50 (depends on 49)

The method of claim 49, wherein the biotype is a bacteria strain that has the same carbohydrate fermentation pattern as the bacteria strain deposited under accession number DSM 14294.

### Claim 51 (depends on 32)

The method of claim 32, wherein the composition further comprises a pharmaceutically acceptable excipient or carrier.
